Figure 2 | Scientific Reports

Figure 2

From: In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug

Figure 2

The effect of PCC0104005 on MK-801-induced hyperlocomotion in rats. Rats were administered an oral dose of vehicle alone (0.5% methylcellulose, 1 ml/kg), PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (1.5 mg/kg) or risperidone (0.2 mg/kg) 1 h before test. Then, all animals were intraperitoneally injected with 0.9% saline or MK-801(0.3 mg/kg) 10 minutes before test. Locomotor activity was recorded for 10–20 minutes after the intraperitoneal injection. Results are presented as mean ± S.E.M. (n = 8). *P < 0.05, **P < 0.01 model group vs. the control group, #P < 0.05, ##P < 0.01 drug delivery groups vs. the model group.

Back to article page